• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

滤泡树突状细胞的进入是小鼠慢性淋巴细胞白血病 B 细胞激活和增殖的关键步骤。

Access to follicular dendritic cells is a pivotal step in murine chronic lymphocytic leukemia B-cell activation and proliferation.

机构信息

Department of Tumor Genetics and Immunogenetics, Max-Delbrück-Center for Molecular Medicine, MDC, Berlin, Germany.

Department of Hematology, Oncology and Tumorimmunology, Max-Delbrück-Center for Molecular Medicine, MDC, Berlin, Germany.

出版信息

Cancer Discov. 2014 Dec;4(12):1448-65. doi: 10.1158/2159-8290.CD-14-0096. Epub 2014 Sep 24.

DOI:10.1158/2159-8290.CD-14-0096
PMID:25252690
Abstract

UNLABELLED

In human chronic lymphocytic leukemia (CLL) pathogenesis, B-cell antigen receptor signaling seems important for leukemia B-cell ontogeny, whereas the microenvironment influences B-cell activation, tumor cell lodging, and provision of antigenic stimuli. Using the murine Eμ-Tcl1 CLL model, we demonstrate that CXCR5-controlled access to follicular dendritic cells confers proliferative stimuli to leukemia B cells. Intravital imaging revealed a marginal zone B cell-like leukemia cell trafficking route. Murine and human CLL cells reciprocally stimulated resident mesenchymal stromal cells through lymphotoxin-β-receptor activation, resulting in CXCL13 secretion and stromal compartment remodeling. Inhibition of lymphotoxin/lymphotoxin-β-receptor signaling or of CXCR5 signaling retards leukemia progression. Thus, CXCR5 activity links tumor cell homing, shaping a survival niche, and access to localized proliferation stimuli.

SIGNIFICANCE

CLL and other indolent lymphoma are not curable and usually relapse after treatment, a process in which the tumor microenvironment plays a pivotal role. We dissect the consecutive steps of CXCR5-dependent tumor cell lodging and LTβR-dependent stroma-leukemia cell interaction; moreover, we provide therapeutic solutions to interfere with this reciprocal tumor-stroma cross-talk.

摘要

未标记

在人类慢性淋巴细胞白血病(CLL)发病机制中,B 细胞抗原受体信号似乎对白血病 B 细胞发生很重要,而微环境影响 B 细胞激活、肿瘤细胞黏附以及提供抗原刺激。我们使用 Eμ-Tcl1 小鼠 CLL 模型证明,CXCR5 控制对滤泡树突状细胞的访问为白血病 B 细胞提供了增殖刺激。活体成像显示了边缘区 B 细胞样白血病细胞的迁移途径。小鼠和人类 CLL 细胞通过淋巴毒素-β-受体激活相互刺激常驻间充质基质细胞,导致 CXCL13 分泌和基质区室重塑。抑制淋巴毒素/淋巴毒素-β-受体信号或 CXCR5 信号会延迟白血病进展。因此,CXCR5 活性将肿瘤细胞归巢、形成生存生态位以及获得局部增殖刺激联系起来。

意义

CLL 和其他惰性淋巴瘤无法治愈,通常在治疗后复发,在此过程中肿瘤微环境起着关键作用。我们剖析了 CXCR5 依赖性肿瘤细胞黏附和 LTβR 依赖性基质-白血病细胞相互作用的连续步骤;此外,我们提供了治疗解决方案来干扰这种互惠的肿瘤-基质交叉对话。

相似文献

1
Access to follicular dendritic cells is a pivotal step in murine chronic lymphocytic leukemia B-cell activation and proliferation.滤泡树突状细胞的进入是小鼠慢性淋巴细胞白血病 B 细胞激活和增殖的关键步骤。
Cancer Discov. 2014 Dec;4(12):1448-65. doi: 10.1158/2159-8290.CD-14-0096. Epub 2014 Sep 24.
2
Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells.使用Syk抑制剂TAK-659抑制BCR信号传导可防止慢性淋巴细胞白血病细胞中的基质介导信号传导。
Oncotarget. 2017 Jan 3;8(1):742-756. doi: 10.18632/oncotarget.13557.
3
Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.脾酪氨酸激酶抑制可预防慢性淋巴细胞白血病中趋化因子和整合素介导的基质保护作用。
Blood. 2010 Jun 3;115(22):4497-506. doi: 10.1182/blood-2009-07-233692. Epub 2010 Mar 24.
4
B cells control the migration of a subset of dendritic cells into B cell follicles via CXC chemokine ligand 13 in a lymphotoxin-dependent fashion.B细胞通过CXC趋化因子配体13以淋巴毒素依赖的方式控制一部分树突状细胞向B细胞滤泡的迁移。
J Immunol. 2002 May 15;168(10):5117-23. doi: 10.4049/jimmunol.168.10.5117.
5
CXCR5-mediated shaping of the lymphoid follicle in chronic lymphocytic leukemia.CXCR5 介导的慢性淋巴细胞白血病中淋巴滤泡的形成。
Cancer Discov. 2014 Dec;4(12):1374-6. doi: 10.1158/2159-8290.CD-14-1204.
6
Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration.选择性新型脾酪氨酸激酶(Syk)抑制剂可抑制慢性淋巴细胞白血病 B 细胞的激活和迁移。
Leukemia. 2012 Jul;26(7):1576-83. doi: 10.1038/leu.2012.24. Epub 2012 Feb 7.
7
Role of spleen tyrosine kinase in the pathogenesis of chronic lymphocytic leukemia.脾酪氨酸激酶在慢性淋巴细胞白血病发病机制中的作用
Leuk Lymphoma. 2014 Dec;55(12):2699-705. doi: 10.3109/10428194.2014.891026. Epub 2014 Mar 18.
8
Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia.趋化因子受体CXCR5及其配体CXCL13在B细胞慢性淋巴细胞白血病中的过表达
Blood. 2007 Nov 1;110(9):3316-25. doi: 10.1182/blood-2007-05-089409. Epub 2007 Jul 25.
9
The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression.酪氨酸激酶Syk通过蛋白激酶Cδ(PKCδ)和蛋白酶体依赖性的Mcl-1表达调控,调节慢性淋巴细胞白血病B细胞的存活。
Oncogene. 2009 Sep 17;28(37):3261-73. doi: 10.1038/onc.2009.179. Epub 2009 Jul 6.
10
AID-expressing germinal center B cells cluster normally within lymph node follicles in the absence of FDC-M1+ CD35+ follicular dendritic cells but dissipate prematurely.表达 AID 的生发中心 B 细胞在缺乏 FDC-M1+CD35+滤泡树突状细胞的情况下仍能正常在淋巴结滤泡内聚集,但会过早消散。
J Immunol. 2013 Nov 1;191(9):4521-30. doi: 10.4049/jimmunol.1300769. Epub 2013 Sep 25.

引用本文的文献

1
Lymphoid stroma in all its states.处于所有状态的淋巴样基质。
Front Immunol. 2025 Jul 16;16:1633235. doi: 10.3389/fimmu.2025.1633235. eCollection 2025.
2
Increased STAT3 Phosphorylation in CD4 T-Cells of Treated Patients with Chronic Lymphocytic Leukemia and Changes in Circulating Regulatory T-Cell Subsets Relative to Tumor Mass Distribution Value and Disease Duration.慢性淋巴细胞白血病经治疗患者CD4 T细胞中STAT3磷酸化增加以及循环调节性T细胞亚群相对于肿瘤肿块分布值和疾病持续时间的变化。
Biomedicines. 2025 May 15;13(5):1204. doi: 10.3390/biomedicines13051204.
3
Tumor microenvironment as a novel therapeutic target for lymphoid leukemias.
肿瘤微环境作为淋巴细胞白血病的新型治疗靶点。
Ann Hematol. 2025 Mar;104(3):1367-1386. doi: 10.1007/s00277-025-06237-w. Epub 2025 Feb 25.
4
Mouse models of chronic lymphocytic leukemia and Richter transformation: what we have learnt and what we are missing.慢性淋巴细胞白血病和 Richter 转化的小鼠模型:我们学到了什么,以及我们还缺少什么。
Front Immunol. 2024 Jun 6;15:1376660. doi: 10.3389/fimmu.2024.1376660. eCollection 2024.
5
CXCL13 Positive Cells Localization Predict Response to Anti-PD-1/PD-L1 in Pulmonary Non-Small Cell Carcinoma.CXCL13阳性细胞定位可预测肺非小细胞癌对抗PD-1/PD-L1治疗的反应
Cancers (Basel). 2024 Feb 7;16(4):708. doi: 10.3390/cancers16040708.
6
The Role of the Microenvironment and Cell Adhesion Molecules in Chronic Lymphocytic Leukemia.微环境和细胞粘附分子在慢性淋巴细胞白血病中的作用
Cancers (Basel). 2023 Oct 26;15(21):5160. doi: 10.3390/cancers15215160.
7
CXC chemokine ligand 13 and galectin-9 plasma levels collaboratively provide prediction of disease activity and progression-free survival in chronic lymphocytic leukemia.CXC 趋化因子配体 13 和半乳糖凝集素-9 的血浆水平共同提供了慢性淋巴细胞白血病疾病活动度和无进展生存期的预测。
Ann Hematol. 2024 Mar;103(3):781-792. doi: 10.1007/s00277-023-05540-8. Epub 2023 Nov 9.
8
Chronic Lymphocytic Leukemia: Disease Biology.慢性淋巴细胞白血病:疾病生物学。
Acta Haematol. 2024;147(1):8-21. doi: 10.1159/000533610. Epub 2023 Sep 16.
9
NF-kB and the CLL microenvironment.核因子-κB与慢性淋巴细胞白血病微环境
Front Oncol. 2023 Mar 30;13:1169397. doi: 10.3389/fonc.2023.1169397. eCollection 2023.
10
CD160 receptor in CLL: Current state and future avenues.慢性淋巴细胞白血病中 CD160 受体:现状与未来研究方向。
Front Immunol. 2022 Nov 7;13:1028013. doi: 10.3389/fimmu.2022.1028013. eCollection 2022.